# Efficacy of Piperacillin-tazobactam as Empirical Antimicrobial Therapy for VAP Among ESBL-E Carriers.

> **NCT04276480** · NA · COMPLETED · sponsor: **University Hospital, Bordeaux** · enrollment: 9 (actual)

## Conditions studied

- Enterobacteriaceae Infections

## Interventions

- **DRUG:** Piperacillin-tazobactam

## Key facts

- **NCT ID:** NCT04276480
- **Lead sponsor:** University Hospital, Bordeaux
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-16
- **Primary completion:** 2024-04-22
- **Final completion:** 2024-04-22
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2024-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04276480

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04276480, "Efficacy of Piperacillin-tazobactam as Empirical Antimicrobial Therapy for VAP Among ESBL-E Carriers.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04276480. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*